Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: August 19, 2010
Last updated: April 7, 2015
Last verified: April 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 19, 2014